Drug Profile
1ST 103
Alternative Names: 1ST 103Latest Information Update: 10 Jan 2023
Price :
$50
*
At a glance
- Originator 1St Biotherapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease; Amyotrophic lateral sclerosis; Parkinson's disease
Most Recent Events
- 10 Jan 2023 1ST 103 is still in early research development for Parkinson's disease, Alzheimer's disease and Amyotrophic lateral sclerosis in South Korea (1St Biotherapeutics pipeline, January 2023)
- 10 Jan 2023 Early research in Alzheimer's disease in South Korea (unspecified route) (1St Biotherapeutics pipeline, January 2023)
- 10 Jan 2023 Early research in Parkinson's disease in South Korea (unspecified route) (1St Biotherapeutics pipeline, January 2023)